Person: TÜRK, HACI MEHMET
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Organizational Unit
Job Title
Last Name
TÜRK
First Name
HACI MEHMET
Name
68 results
Search Results
Now showing 1 - 10 of 68
- PublicationMetadata onlyDiffusion Tensor Imaging of Brain Metastases in Patients with Breast Cancer According to Molecular Subtypes.(2020-06-21T00:00:00Z) Turk, HM; Sari, L; Yurtsever, I; Yabaci, A; Peker, AA; Alkan, ALPAY; YURTSEVER, İSMAİL; GÜLTEKİN, MEHMET ALİ; TOPRAK, HÜSEYİN; TÜRK, HACI MEHMET; YABACI TAK, AYŞEGÜL; ALKAN, ALPAY
- PublicationMetadata onlyWorse patient- physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the palliative care working committee of the Turkish Oncology Group (TOG)(2019-10-01T00:00:00Z) Alkan, A.; Yasar, A.; Guc, Z. G.; Gurbuz, M.; Basoglu, T.; Goksu, S. Sezgin; Basal, F. Bugdaycl; TÜRK, HACI MEHMET; Ozdemir, O.; Cinkir, H. Yesil; Guven, D. C.; Kus, T.; Turker, S.; Koral, L.; Karakas, Y.; Ak, N.; Paydas, S.; Karci, E.; Tanriverdi, O.; Senler, F. Cay; TÜRK, HACI MEHMET
- PublicationOpen AccessEMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%(2020-09-01T00:00:00Z) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; ÖZGÜROĞLU, Mustafa; Gogishvili, M.; TÜRK, HACI MEHMET; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Gullo, G.; Lowy, I.; Rietschel, P.; TÜRK, HACI MEHMET
- PublicationMetadata onlyClinicopathological Features of Gastroenteropancreatic Neuroendocrine Neoplasms.(2020-08-01T00:00:00Z) Sekerci, A; Turk, HM; Demir, T; Seker, M; Akcakaya, Adem; Arici, DS; ŞEKERCİ, ABDÜSSELAM; TÜRK, HACI MEHMET; AKÇAKAYA, ADEM
- PublicationMetadata onlyThe Utility and Efficiency of Diffusion Tensor Imaging Values to Determine Epidermal Growth Factor Receptor Gene Mutation Status in Brain Metastasis from Lung Adenocarcinoma; A Preliminary Study(2021-02-01T00:00:00Z) Gültekin, Mehmet Ali; Alkan, Alpay; Yılmaz, Temel Fatih; Yurtsever, İsmail; Atasoy, Bahar; Aliyev, Altay; GÜLTEKİN, MEHMET ALİ; TÜRK, HACI MEHMET; YURTSEVER, İSMAİL; YILMAZ, TEMEL FATİH; ALKAN, ALPAY
- PublicationOpen AccessTurkish Ministry of Health, 2<sup>nd</sup> Turkish Medical General Assembly Clinical Oncology Study Group Report.(2016-01-01) ÖZMEN, V; DAĞOĞLU, N; DEDE, İ; Akçakaya, ADEM; KEREM, M; GÖKSEL, F; ÖZGÜR, E; BAŞKAN, E; YAYLACı, M; CEYDELI, A; BAYKARA, M; Kızıltan, HURİYE ŞENAY; KÖMÜRCÜ, Ş; GÜMÜŞ, M; Türk, HACI MEHMET; DEMIRHAN, R; AKGÜN, A; KADOGLOU, N; YATMAN, E; ELBI, CC; GÜLEÇ, S; SORAN, A; ÖZET, A; KELEŞTIMUR, F; AKÇAKAYA, ADEM; KIZILTAN, HURİYE ŞENAY; TÜRK, HACI MEHMETObjective: There is an increase in the incidence of cancer, and consequently in mortality rates, both in the world and in Turkey. The increase in the incidence and mortality rate of cancer are more prominent in our country as well as in other developing countries. The aim of this workshop was to determine the current status on prevention, screening, early diagnosis and treatment of cancer in our country, to identify related shortcomings, specify solutions and to share these with health system operators, and to aid in implementation of these systems. Developments on palliative care were also evaluated. Materials and methods: The current situation in the practice of clinical oncology, related drawbacks, problems encountered during multidisciplinary approach and their solutions were discussed under several sub-headings during a 3-day meeting organized by the Turkish Ministry of Health (Türkiye Cumhuriyeti Sağlık Bakanlığı-TCSB) with participation of 16 scientists from Turkey and 6 from abroad, and the conclusions were reported. Results: It is expected that the newly established Turkish Health Institutes Association (Türkiye Sağlık Enstitüleri Başkanlığı-TÜSEB) and the National Cancer Institute (Ulusal Kanser Enstitüsü) will provide a new framework in the field of oncology. The current positive findings include the increase in the number of scientists who carry out successful trials in oncology both in Turkey and abroad, the implementation of the national cancer registry program by the Cancer Control Department and the breast cancer registry program by the Turkish Federation of Breast Diseases Societies (Türkiye Meme Hastalıkları Dernekleri Federasyonu-TMHDF), and introduction of Cancer Early Diagnosis, Screening, and Training Centers (Kanser Erken Tanı, Tarama ve Eğitim Merkezi-KETEM) for the application of community-based cancer screening programs. In addition to these, obvious shortcomings related to education, implementation, management and research issues were also determined, and policy and project proposals to address these issues were presented. Collaboration with relevant organizations in the implementation of these studies was supported. Conclusion: Both the incidence and mortality rates of cancer are increasing in Turkey. The widespread deficiencies in population-based screening and in effective treatment lead to an increase in delay in diagnosis and mortality. Despite improvements in data recording, screening and treatment over the last 10 years, extensive, organized, population-based screening programs and fully equipped early diagnosis and treatment centers are required. Enhancement of basic cancer epidemiologic, translational, genetic and molecular research studies is essential in our country. Improvements on pain treatment and palliative care of patients with chronic and terminal cancer are also required.
- PublicationMetadata onlyCemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.(2021-02-13T00:00:00Z) Sezer, Ahmet; Kilickap, Saadettin; Gümüş, Mahmut; Bondarenko, Igor; Özgüroğlu, Mustafa; Gogishvili, Miranda; Turk, HACI MEHMET; Cicin, Irfan; Bentsion, Dmitry; Gladkov, Oleg; Clingan, Philip; Sriuranpong, Virote; Rizvi, Naiyer; Gao, Bo; Li, Siyu; Lee, Sue; McGuire, Kristina; Chen, Chieh-I; Makharadze, Tamta; Paydas, Semra; Nechaeva, Marina; Seebach, Frank; Weinreich, David M; Yancopoulos, George D; Gullo, Giuseppe; Lowy, Israel; Rietschel, Petra; TÜRK, HACI MEHMET
- PublicationMetadata onlyStem cell markers: A guide to neoadjuvant therapy in breast carcinomas(2022-06-01T00:00:00Z) Gücin, Zühal; Büyükpınarbaşılı, Nur; Geçer, Melin; Ersoy, Yeliz Emine; Türk, Hacı Mehmet; Yıldız, Şeyma; Aksoy, Direnç Özlem; GÜCİN, ZÜHAL; GEÇER, MELİN; ERSOY, YELIZ EMINE; TÜRK, HACI MEHMET; YILDIZ, ŞEYMABACKGROUND: In recent years, stem cells have been defined as the main cell population responsible for resistance to anticancer therapies. AIM: This study aims to investigate potential associations between the stem cell population and the degree of tumor regression in breast carcinomas treated with neoadjuvant therapy. SETTINGS AND DESIGN: The study included 92 patients with breast carcinoma who received neoadjuvant therapy. Tumor regression was defined based on Miller and Payne grading system. Patients with grade 1 or 2 regression on a 5‑point scale were included in group 1 (n = 37), grade 3 regression in group 2 (n = 32), and grade 4 or 5 regression in group 3 (n = 23). MATERIALS AND METHODS: Immunohistochemical staining was performed on paraffin block sections of every case using CD44, CD24, CD29, CD133, ID4, and ALDH1 antibodies to detect stem cells. STATISTICAL ANALYSIS USED: IBM Statistical Package for the Social Sciences (SPSS), version 23.0 (IBM Corp., Armonk, NY, USA) software was used for statistical analyses, and a P value less than 0.05 was considered statistically significant. RESULTS: Histologically high‑grade tumors are more common in the near‑complete/complete response group (P = 0.004). HER2‑positive tumors were more common in the complete/ near‑complete response group (P = 0.054). Tumor cells positive for stem cell markers CD44 and CD24 were more common in the poor response group (P = 0.027 and P = 0.001, respectively). CD29 expression was reduced in the posttreatment residual tumor tissue in the near‑complete/complete response group. CONCLUSION: High CD44 and CD24 expression may be a predictor of poor response/nonresponse to neoadjuvant therapy in breast carcinomas. KEY WORDS: Breast Cancers, neoadjuvant treatment, stem cell markers, stem cells, tumor regression grade
- PublicationMetadata onlyDoes primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study(2020-03-01T00:00:00Z) Yildiz, Birol; Kucukarda, Ahmet; Gokyer, Ali; Demiray, Atike Gokcen; PAYDAŞ, SEMRA; Aral, Ipek Pinar; Gumusay, Ozge; Bilici, Ahmet; Akdeniz, Nadiye; Bahceci, Aykut; Demir, Hacer; Esin, Ece; Uyeturk, Ummugul; Okten, Ilker Nihat; Erturk, Ismail; TÜRK, HACI MEHMET; Topaloglu, Ulas Serkan; Basoglu, Tugba; Turhal, Nazim Serdar; Cinkir, Havva Yesil; Menekse, Serkan; Cakmak, Yagmur; Urun, Yuksel; Acar, Ramazan; Kut, Engin; Dal, Pinar; Sakalar, Teoman; Aktepe, Oktay Halit; Karadurmus, Nuri; TÜRK, HACI MEHMETPurpose: The purpose of this study was to determine whether primary tumor localization may be a risk factor for relapse and survival in seminomatous germ cell tumors (GCT) patients.
- PublicationMetadata onlyAn unusual presentation of extramedullary plasmacytoma in testis and review of the literature.(2010-12-01T00:00:00Z) Turk, HACI MEHMET; KOMURCU, S; OZET, A; KUZHAN, O; GÜNHAN, O; TÜRK, HACI MEHMET